Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

EADV 2020 | References: SARS-CoV-2 (COVID-19) pandemic and psoriasis management

Other 2020

  1. Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther. Published online May 1, 2020:e13475.
  2. Fougerousse A-C, Perrussel M, Bécherel P-A, et al. Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19. J Eur Acad Dermatol Venereol. Published online June 21, 2020.
  3. Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis - insights from a global registry-based study. J Allergy Clin Immunol. Published online October 16, 2020.
  4. Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020;183(2):373-374.
  5. Brenner EJ, Ungaro RC, Colombel JF, Kappelman MD. SECURE-IBD Database Public Data Update. covidibd.org. Accessed on 10/31/2020.
  6. Ricardo JW, Lipner SR. Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. Published online May 27, 2020:e13687.

Search:

Filter by Topic:


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK